Corbus Pharmaceuticals (CRBP) 10-K 10 Feb 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 02, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	CRBP
Entity Registrant Name	CORBUS PHARMACEUTICALS HOLDINGS, INC.
Entity Central Index Key	1595097
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		25,941,175
Entity Public Float		$39,376,913

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$6,262,445	$303,020
Prepaid expenses	270,556	2,500
Total current assets	6,533,001	305,520
Restricted cash	13,728
Property and equipment, net	54,044
Total assets	6,600,773	305,520
Current liabilities:
Accounts payable	344,160	181,471
Accrued interest payable		77,140
Accrued expenses	249,491	63,488
Derivative warrant liability		19,932
Notes payable-current	144,389	306,835
Total current liabilities	738,040	648,866
Notes payable		331,243
Total liabilities	738,040	980,109
Commitments and Contingencies
Stockholders' equity (deficit)
Preferred Stock $0.0001 par value:10,000,000 share authorized, no shares issued and outstanding at December 31, 2014
Common stock, $0.0001 par value; 150,000,000 shares authorized, 25,938,332 and 6,964,788 shares issued and outstanding at December 31, 2014 and December 31, 2013	2,594	696
Additional paid-in capital	10,287,214	102,696
Accumulated deficit	-4,427,075	-1,886,590
Total stockholders' equity (deficit)	5,862,733	-1,783,198
Total liabilities, preferred stock and stockholders equity (deficit)	6,600,773	305,520
Series A Convertible Preferred Stock [Member]
JB Therapeutics' Series A Preferred Stock, $0.0001 Par Value:
Preferred stock, value		1,106,609
Series A Non-Convertible Preferred Stock [Member]
JB Therapeutics' Series A Preferred Stock, $0.0001 Par Value:
Preferred stock, value		$2,000

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value	$0.00
Preferred stock, shares authorized	10,000,000
Preferred stock, shares issued	0
Preferred stock, shares outstanding	0
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	25,938,332	6,964,788
Common stock, shares outstanding	25,938,332	6,964,788
Common stock, par value	$0.00	$0.00
Series A Convertible Preferred Stock [Member]
Preferred Stock, shares designated		2,483,690
Preferred Stock, shares issued		1,835,212
Preferred Stock, shares outstanding		1,835,212
Preferred Stock, liquidation preference		$1,106,609
Preferred Stock, par value		$0.00
Preferred stock, shares issued		198,808
Series A Non-Convertible Preferred Stock [Member]
Preferred Stock, shares designated		200,000
Preferred Stock, shares issued		200,000
Preferred Stock, shares outstanding		200,000
Preferred Stock, liquidation preference		$200,000
Preferred Stock, par value		$0.00

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Operating expenses:
Research and development	$1,255,535	$210,670
General and administrative	1,391,638	346,606
Total operating expenses	2,647,173	557,276
Operating loss	-2,647,173	-557,276
Other income (expense):
Interest expense	-24,021	-45,114
Forgiveness of interest on note payable	7,466
Interest income	2,115	754
Gain on the settlement of debt	145,006
Change in fair value of warrant liability	-28,448	1,978
Foreign currency exchange (loss) gain	4,570	-2,692
Other expense, net	106,688	-45,074
Net loss	($2,540,485)	($602,350)
Net loss per share, basic and diluted	($0.13)	($0.09)
Weighted average number of common shares outstanding, basic and diluted	20,159,861	6,964,788

Statements_of_Preferred_Stock_

Statements of Preferred Stock and Stockholders' Equity (Deficit) (USD $)	Total	Series A Convertible Preferred Stock [Member]	Series A Non-Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Deficit Accumulated During the Development Stage [Member]
Beginning balance at Dec. 31, 2012	($1,186,989)	$986,609	$2,000	$696	$96,555	($1,284,240)
Beginning balance, shares at Dec. 31, 2012		1,636,404	200,000	6,964,788
Issuance of Series A preferred stock/ common stock at inception of Corbus		120,000
Issuance of Series A preferred stock/ common stock at inception of Corbus, shares		198,808
Stock compensation expense	6,141				6,141
Net loss	-602,350					-602,350
Ending balance at Dec. 31, 2013	-1,783,198	1,106,609	2,000	696	102,696	-1,886,590
Ending balance, shares at Dec. 31, 2013		1,835,212	200,000	6,964,788
Issuance of Series A preferred stock/ common stock at inception of Corbus				600	-600
Issuance of Series A preferred stock/ common stock at inception of Corbus, shares				6,000,000
Conversion of Series A convertible preferred stock into common stock upon reverse acquisition	1,108,609	-1,106,609	-2,000	204	1,108,405
Conversion of Series A convertible preferred stock into common stock upon reverse acquisition, Shares		-1,835,212	-200,000	2,035,212
Issuance of common stock in private placement, net of issuance costs of $1,857,668	8,402,332			1,026	8,401,306
Issuance of common stock in private placement, shares				10,260,000
Issuance of common stock in exchange for settlement of debt	396,192			54	396,138
Issuance of common stock in exchange for settlement of debt, shares				541,948
Stock compensation expense	193,120				193,120
Issuance of common stock upon exercise of warrants	33,333			5	33,328
Issuance of common stock upon exercise of warrants, shares				48,693
Issuance of common stock upon exercise of stock options	4,450			9	4,441
Issuance of common stock upon exercise of stock options, shares	87,691			87,691
Reclasssification of derivative warrant liability	48,380				48,380
Net loss	-2,540,485					-2,540,485
Ending balance at Dec. 31, 2014	$5,862,733			$2,594	$10,287,214	($4,427,075)
Ending balance, shares at Dec. 31, 2014				25,938,332

Statements_of_Preferred_Stock_1

Statements of Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) (USD $)	Dec. 31, 2014
Statement of Stockholders' Equity [Abstract]
Stock issuance costs	$1,857,668

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	($2,540,485)	($602,350)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	193,120	6,141
Depreciation	10,405
(Gain) loss on foreign exchange	-4,570	2,692
Gain on settlement of notes payable, accrued interest and accounts payable	-145,006
Forgiveness of interest on notes payable	-7,466
Changes in fair value of derivative warrant liability	28,448	-1,978
Non-cash interest expense	29,861	41,543
Changes in operating assets and liabilities:
Increase in restricted cash	-13,728
Decrease in prepaid expenses	-268,056
Increase in accounts payable	170,239	131,849
Increase (decrease) in accrued expenses	186,002	33,478
Net cash used in operating activities	-2,361,236	-366,715
Cash flows from investing activities:
Purchases of property and equipment	-64,448
Net cash (used in) provided by investing activities	-64,448
Cash flows from financing activities:
Proceeds from convertible bridge notes	0	0
Proceeds from issuance of notes payable	192,000	7,252
Principal payments on notes payable	-247,006
Proceeds from issuance on common stock	10,305,161
Issuance costs incurred common stock financings	-1,865,046
Net cash provided by financing activities	8,385,109	127,252
Net increase (decrease) in cash and cash equivalents	5,959,425	-239,463
Cash and cash equivalent at beginning of the period	303,020	542,483
Cash and cash equivalent at end of the period	6,262,445	303,020
Supplemental disclosure of cash flow information and non cash transactions:
Conversion of notes payable, accrued interest and accounts payable into common stock and a warrant	396,000
Reclassification of derivative warrant liability to equity	48,380
Series A Convertible Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Series A convertible preferred stock		120,000
Supplemental disclosure of cash flow information and non cash transactions:
Conversion of Series A preferred stock into common stock	$1,108,609

Nature_of_Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Nature of Operations
	1	NATURE OF OPERATIONS
	Business
	Corbus Pharmaceuticals Holdings, Inc. (“CPHI” or “the Company”) is a clinical stage biopharmaceutical company, focused on the development and commercialization of therapeutics to treat rare life-threating, rare inflammatory fibrotic diseases. Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s business is subject to significant risks and uncertainties and the Company will be dependent on raising substantial additional capital before it becomes profitable and it may never achieve profitability.
	Reverse Acquisition
	JB Therapeutics Inc. (“JB Therapeutics”), was incorporated on April 24, 2009 under the laws of the State of Delaware. CPHI was incorporated on December 18, 2013 under the laws of the State of Delaware. On April 11, 2014, JB Therapeutics Inc. completed a reverse acquisition with CPHI. Upon the consummation of the reverse acquisition, JB Therapeutics became a wholly owned subsidiary of CPHI and changed its name to Corbus Pharmaceuticals, Inc. CPHI continues to operate the business of JB Therapeutics. All the references to the “Company” for activities prior to the reverse merger are to JB Therapeutics activities.
	As part of the reverse acquisition, CPHI issued 9,000,000 shares of common stock to holders of JB Therapeutics common and preferred stock in exchange for a total of 5,964,649 common shares outstanding on an as converted basis. In addition, the holders of warrants to purchase common stock of JB Therapeutics received warrants, or the Replacement Warrants, to purchase 377,839 shares of CPHI common stock with an exercise price of ranging from $0.60 to $0.66. In addition, holders of JB Therapeutics Series A preferred stock received warrants to purchase 917,612 shares of common stock of CPHI. Finally, holders of outstanding options of JB Therapeutics received, in substitution for such options, options made pursuant to the Corbus 2014 Equity Incentive Plan to purchase an aggregate of 905,334 shares of CPHI common stock with exercise prices ranging from $0.11 to $0.17 per share. All share and per share amounts presented in these consolidated financial statements for the years ended December 31, 2014 and 2013 have been retroactively restated to reflect the 1.5089 exchange ratio of JB Therapeutics shares for CPHI shares in the reverse acquisition. Immediately prior to the reverse acquisition, CPHI had 6,000,000 shares outstanding.
	The reverse acquisition was accounted for as a recapitalization since the formation of CPHI was formed solely to effect the reverse acquisition and a private placement of equity and CPHI had no prior operations or net monetary assets. Thus, JB Therapeutics is deemed to be the accounting acquirer and successor entity and the historical financial statements are those of JB Therapeutics as the accounting acquirer. Following the reverse acquisition, the management of JB Therapeutics became the management of CPHI. At the date of the reverse acquisition, the 6,000,000 outstanding shares of CPHI are reflected as an issuance of common stock to the prior holders of CPHI. CPHI had no net monetary assets as of the reverse acquisition so the issuance was recorded as a reclassification between additional paid-in-capital and par value of common stock. On April 11, 2014 and in three subsequent closings, CPHI completed a private placement of equity, raising net proceeds of approximately $8,402,000 (the “2014 Private Placement”) (See Note 9).

Liquidity

Liquidity	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Liquidity	2	LIQUIDITY
	The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred recurring losses since inception and as of December 31, 2014, had an accumulated deficit of $4,427,000. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research funding, development of its product candidates and its preclinical programs, strategic alliances and the development of its administrative organization. The Company expects the current cash on hand to be sufficient to meet its operating and capital requirements through at least December 2015. In addition, the Company will need to raise significant additional capital to fund the clinical trials for Resunab, its continued research and development efforts, to expand its business, to pursue strategic investments, to take advantage of financing opportunities, and other operating needs. The sale of equity and convertible debt securities may result in dilution to the Company’s stockholders and those securities may have rights senior to those of the Company’s common shares. If the Company raises additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict the Company’s operations. Any other third-party funding arrangement could require the Company to relinquish valuable rights. The source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the progress of the Company’s clinical development programs. Funding may not be available when needed, at all, or on terms acceptable to the Company. Lack of necessary funds may require the Company, among other things, to delay, scale back or eliminate some or all of the Company’s planned clinical trials.

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies	3	SIGNIFICANT ACCOUNTING POLICIES
	A summary of the significant accounting policies followed by the Company in the preparation of the financial statements is as follows:
	Use of Estimates
	The process of preparing financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and changes in estimates may occur. The most significant estimates are related to stock based compensation, the value of derivative instruments and the accrual of research and clinical obligations.
	The Company has granted stock options at exercise prices not less than the fair value of its common stock as determined by the board of directors, with input from management. The Company’s board of directors determined the estimated fair value of the common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the historic prices at which the Company sold shares of preferred stock.
	Cash and Cash Equivalents
	The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within three months from date of purchase to be cash equivalents. Marketable investments are those with original maturities in excess of three months. At December 31, 2014 and 2013, cash equivalents were comprised of money market funds. The Company had no marketable investments at December 31, 2014 and 2013. Cash and cash equivalents consist of the following:
			December 31,
			2014			2013
	Cash		$	10,974		$	100,761
	Money market fund			6,251,471			202,259
			$	6,262,445		$	303,020
	Restricted Cash
	Restricted cash as of December 31, 2014 was $13,728 and represented a stand-by letter of credit in favor of a landlord (See Note 5).
	Financial Instruments
	The carrying amounts reported in the consolidated balance sheet for cash and cash equivalents and accounts payable approximate fair value based on the short-term nature of these instruments. The carrying value of loans payable approximate their fair value due to the market terms.
	Property and Equipment
	Property and Equipment consists of the following:
			December 31,
			2014			2013
	Computer hardware and software		$	17,179		$	—
	Office furniture and equipment			27,960			—
	Leasehold improvements			19,310			—
	Less: accumulated depreciation			(10,405	)		—
	Property and equipment, net		$	54,044		$	—
	The estimated life for all Property and Equipment is 3 years.
	Research and Development Expenses
	Costs incurred for research and development are expensed as incurred. The Company records payments received from research grants as a reduction in Research and Development on the Statement of Operations. For the years ended December 31, 2014 and 2013, the Company reduced Research and Development expense by $49,000 and $205,000, respectively, for research grants.
	Accruals for Research and Development Expenses and Clinical Trials
	As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate trial expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account discussion with applicable personnel and outside service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the years ended December 31, 2014 and 2013, there were no material adjustments to the Company’s prior period estimates of accrued expenses for clinical trials.
	Concentrations of Credit Risk
	The Company has no significant off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company may from time to time have cash in banks in excess of Federal Deposit Insurance Corporation insurance limits.
	Segment Information
	Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as principally one operating segment, which is developing and commercializing therapeutics to treat rare life-threating, rare inflammatory fibrotic diseases. As of December 31, 2014 and 2013, all of the Company’s assets were located in the United States.
	Income Taxes
	For federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in which differences are expected to reverse. A valuation allowance is recorded to reduce a net deferred tax benefit when it is more likely than not that the tax benefit from the deferred tax assets will not be realized. Accordingly, the Company has provided a valuation allowance equal to 100% of the tax benefit in order to eliminate the deferred tax assets amounts. Tax positions taken or expected to be taken in the course of preparing the Company’s tax returns are required to be evaluated to determine whether the tax positions are “more-likely-than-not” of being sustained by the applicable tax authority.
	Tax positions not deemed to meet a more-likely-than-not threshold would be recorded as a tax expense in the current year. There were no uncertain tax positions that require accrual or disclosure to the financial statements as of December 31, 2014 or 2013.
	Impairment of Long-lived Assets
	The Company continually monitors events and changes in circumstances that could indicate that carrying amounts of long-lived assets may not be recoverable. An impairment loss is recognized when expected cash flows are less than an asset’s carrying value. Accordingly, when indicators of impairment are present, the Company evaluates the carrying value of such assets in relation to the operating performance and future undiscounted cash flows of the underlying assets. The Company’s policy is to record an impairment loss when it is determined that the carrying value of the asset may not be recoverable. No impairment charges were recorded for the years ended December 31, 2014 and 2013.
	Share-based Payments
	The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement of operations over the service period based on a measurement of fair value for each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. Due to its limited operating history, limited number of sales of its common stock and limited history of its shares being publicly traded, the Company estimates its volatility in consideration of a number of factors including the volatility of comparable public companies.
	Derivative Instruments
	The Company generally does not use derivative instruments to hedge exposures to cash-flow or market risks; however, certain warrants to purchase common stock that do not meet the requirements for classification as equity are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. Such financial instruments are initially recorded at fair value with subsequent changes in fair value charged (credited) to operations in each reporting period. If these instruments subsequently meet the requirements for classification as equity, the Company reclassifies the fair value to equity.
	Net Loss Per Common Share
	Basic net loss per share of the Company’s common stock has been computed by dividing net loss by the weighted average number of shares outstanding during the period. Diluted net income per share of the Company’s common stock has been computed by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding stock options, warrants and convertible securities. Diluted net loss per share of the Company’s common stock has been computed by dividing the net loss for the period by the weighted average number of shares of the Company’s common stock outstanding during such period. In a net loss period, options, warrants and convertible securities are anti-dilutive and therefore excluded from diluted loss per share calculations. The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2014 and 2013:
			Years Ended December 31,
			2014			2013
	Basic and diluted net loss per share of common stock:
	Net loss		$	(2,540,485	)	$	(602,350	)
	Net loss applicable to common stockholders			(2,540,485	)		(602,350	)
	Weighted average shares of common stock outstanding			20,159,861			6,964,788
	Net loss per share of common stock-basic and diluted		$	(0.13	)	$	(0.09	)
	The following potentially dilutive securities outstanding at December 31, 2014 and 2013 have been excluded from the computation of dilutive weighted average shares outstanding as the inclusion would be antidilutive.
			December 31,
			2014			2013
	Preferred stock			—			1,646,157
	Warrants			13,709,977			329,617
	Stock options			3,556,691			528,154
				17,266,668			2,503,928
	Recent Accounting Pronouncements
	In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern, which states management should evaluate whether there are conditions or events, considered in the aggregate, that raise a substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Management’s evaluation should be based on
	relevant conditions and events that are known and likely to occur at the date that the financial statements are issued. The standard update will be effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter, however, early application is permitted. Management does not expect the adoption of ASU 2014-15 to have material impact on the Company’s consolidated financial statements, although there may be additional disclosures upon adoption.

Fair_Value_of_Assets_and_Liabi

Fair Value of Assets and Liabilities	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value of Assets and Liabilities	4	FAIR VALUE OF ASSETS AND LIABILITIES
	The Company groups its assets and liabilities measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.
	Level 1—Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.
	Level 2—Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3—Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.
	The Company uses valuation methods and assumptions that consider, among other factors, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. The Company had no assets or liabilities classified as Level 1 or Level 2. Certain warrants issued for professional services (Note 10) were classified as Level 3. The fair values of these instruments were determined using models based on market observable inputs and management judgment. There were no material re-measurements of fair value during the years ended December 31, 2014 and 2013 with respect to financial assets and liabilities, other than those assets and liabilities that are measured at fair value on a recurring basis.
	The Company had valued certain warrants as a derivative liability at December 31, 2013 and due to a modification in the terms of these warrants (See Note 11), the derivative liability was reclassified at June 30, 2014 to Additional Paid in Capital. The warrant derivative liability was re-measured at June 30, 2014 prior to reclassification using the Black-Scholes option pricing model based on the following assumptions:
			As of June 30,
			2014
	Risk free interest rate			1.25	%
	Expected dividend yield			0	%
	Contractual term			3.97
	Expected volatility			66	%
	As of December 31, 2014 there were no derivative warrant liabilities.
	Assets and liabilities measured at fair value on a recurring basis are summarized below:
			December 31, 2014
			Level 1			Level 2		Level 3			Total
	Liabilities:
	Derivative warrant liability at December 31, 2013		$	—		$	—	$	19,932		$	19,932
	Change in fair value of the derivative warrant liability			—			—		28,448			28,448
	Reclassification of derivative warrant liability			—			—		(48,380	)		(48,380	)
	Derivative warrant liability at December 31, 2014		$	—		$	—	$	—		$	—
			31-Dec-13
			Level 1			Level 2		Level 3			Total
	Liabilities:
	Derivative warrant liability at December 31, 2012		$	—		$	—	$	—		$	—
	Derivative warrant liability recored for warrants issued			—			—		21,910			21,910
	Change in fair value of the derivative warrant liability			—			—		(1,978	)		(1,978	)
	Derivative warrant liability at December 31, 2013		$	—		$	—	$	19,932		$	19,932

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	5	COMMITMENTS AND CONTINGENCIES
	Operating Lease Commitment
	On May 30, 2014, the Company entered into a commercial lease for 2,387 square feet of office space in Norwood, MA. The lease commenced on July 1, 2014 and is for a three year term. The lease also requires a standby letter of credit of $13,728 payable in favor of the landlord (See Note 3).
	Pursuant to the terms of the Company’s non-cancelable lease agreements in effect at December 31, 2014, the future minimum rent commitments are as follows:
	2015		$	55,498
	2016			56,511
	2017			28,464
	Total		$	140,473
	Total rent expense for the year ended December 31, 2014, including month-to-month leases, was $35,550. There was no rent expense incurred for the year ended December 31, 2013.

Notes_Payable

Notes Payable	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Notes Payable	6	NOTES PAYABLE
	The Company entered into notes payable agreements with vendors in lieu of making payments due on accounts payable to these vendors. Interest accrued on these interest bearing notes payables at an annual rate of 7% with accrued interest and principal due at maturity. In August 2014, the Company entered into a settlement agreement with a vendor for the repayment of $631,000 which included $531,000 in notes payable, $93,000 of accrued interest and $7,000 of accounts payable. Under the terms of the settlement agreement, the Company paid the vendor $90,000 and issued 541,948 shares of common stock and a warrant to purchase 162,539 shares of common cost exercisable at $1.00 per share with a five year term. The Company valued the common stock at $341,000 and estimated the fair value of the warrant to be $55,000 based on a Black-Sholes valuation. The Company estimated the fair value of the common stock to be $.63 per share based upon the 2014 Private Placement in which the Company sold one share of common stock and one warrant for $1.00. The Company estimated the fair value of each warrant to be $0.37 based on a Black Scholes valuation model. For the year ended December 31, 2014, the Company recorded a gain on the settlement of $145,000 which was recorded as Other Income on the Statement of Operations.
	The Company also has a note payable outstanding to another vendor with a balance due of $75,244 at September 30, 2014 which has no stated interest rate. The Company had been accruing interest on this note but reached an agreement with the vendor to pay off this note payable with no interest in four equal monthly principal installments of $25,081 and the note was paid off as of December 31, 2014.
	In October 2014, the Company entered into a loan agreement with a financing company for $192,000. The terms of the loan stipulate equal monthly payments of principal and interest payments of $24,293 over an eight month period. Interest accrues on this loan at annual rate of 3.25%.
	Interest expense for notes payable for the years ended December 31, 2014 and 2013 totaled $24,020 and $31,502, respectively.
	Notes payable consisted of the following:
			December 31,
			2014			2013
	Notes payable		$	144,389		$	638,078
	Less: current portion			(144,389	)		(306,835	)
			$	—		$	331,243

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	7	INCOME TAXES
	No provision or benefit for federal or state income taxes has been recorded, as the Company has incurred a net loss for all of the periods presented, and the Company has provided a full valuation allowance against its deferred tax assets.
	At December 31, 2014 and 2013, the Company had federal and Massachusetts net operating loss carryforwards of approximately $1,409,000 and $512,000, respectively, of which federal carryforwards will expire in varying amounts beginning in 2029. Massachusetts net operating losses began to expire in 2014. Utilization of net operating losses may be subject to substantial annual limitations due to the “change in ownership” provisions of the Internal Revenue Code, and similar state provisions. The annual limitations may result in the expiration of net operating losses before utilization. The Company also had research and development tax credit carryforwards at December 31, 2014 of approximately $167,000.
	Significant components of the Company’s net deferred tax asset are as follows:
			December 31,
			2014			2013
	NOL Carryforward		$	1,408,745		$	511,595
	Tax credits			167,127			73,206
	Stock Based Compensation			60,373			2,412
	Other temporary differences			128,093			122,573
	Subtotal			1,764,338			709,786
	Valuation Allowance			(1,764,338	)		(709,786	)
	Net Deferred Tax asset		$	—		$	—
	The Company has maintained a full valuation allowance against its deferred tax assets in all periods presented. A valuation allowance is required to be recorded when it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Since the Company cannot determine that it is more likely than not that it will generate taxable income, and thereby realize the net deferred tax assets, a full valuation allowance has been provided. The Company has no uncertain tax positions at December 31, 2014 and 2013 that would affect its effective tax rate. The Company does not anticipate a significant change in the amount of uncertain tax positions over the next twelve months. Since the Company is in a loss carryforward position, the Company is generally subject to U.S. federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available.
	Income tax benefits computed using the federal statutory income tax rate differs from the Company’s effective tax rate primarily due to the following:
			December 31,
			2014			2013
	Tax provision at statutory rate			34	%		34	%
	State taxes, net of federal benefit			5.03	%		5.09	%
	Permanent differences			-0.47	%		-1.19	%
	Tax Credits			3.37	%		4.2	%
	Other			0.21	%		7.47	%
	Decrease in valuation reserve			-42.14	%		-49.57	%
	Total			0	%		0	%

Series_A_Preferred_Stock

Series A Preferred Stock (Series A [Member])	12 Months Ended
	Dec. 31, 2014
Series A [Member]
Series A Preferred Stock	8	SERIES A PREFERRED STOCK
	In April 2014, in conjunction with the reverse acquisition and financing, 1,835,212 shares of JB Therapeutics’ Series A Convertible Preferred Stock and 200,000 shares of its Series A Non-Convertible Preferred Stock were converted into 2,035,212 shares of the Company’s common stock.
	Prior to the conversion, the Company had classified the Series A Convertible and Series A Non-convertible Preferred Stock outside of permanent equity based upon the terms of the instruments.
	During 2013, the Company issued 198,808 shares of Series A Convertible Preferred Stock which raised net proceeds of $120,000.

Common_Stock

Common Stock	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Common Stock	9	COMMON STOCK
	The Company has authorized 150,000,000 shares of common stock, $0.0001 par value per share, of which 25,938,332 shares and 6,964,788 shares were issued and outstanding as of December 31, 2014 and 2013, respectively.
	On April 11, 2014, in conjunction with the reverse acquisition (See Note 1) and the 2014 Private Placement, the Company issued 6,000,000 shares of common stock to the former shareholders of CPHI and 1,835,212 shares of Series A Convertible Preferred Stock and 200,000 shares of Series A Non-Convertible Preferred Stock were converted into 2,035,212 shares of common stock.
	In August 2014, the Company issued 541,948 shares of common stock to a vendor in connection with a settlement of debt obligation (Note 6).
	In December 2014, the Company issued 87,691 shares of common stock upon the exercise of stock options to purchase common stock and the Company received net proceeds of $4,450.
	In December 2014, the Company issued 33,333 shares of common stock upon the exercise of warrants to purchase 33,333 shares of common stock and the Company received net proceeds of $33,333. Also in December 2014, the Company issued 15,360 shares of common stock upon the exercise of warrants to purchase 21,500 shares of common stock that were exercised under a cashless exercise provision.
	On September 23, 2014, the Company’s board of directors approved a reverse stock split within a range of 1:1.25 to 1:5 (the “Reverse Stock Split Range”) which was subsequently approved by the Company’s stockholders on October 8, 2014. The stockholder approval authorizes the Company to amend its Certificate of Incorporation until, on or before the date that is the earlier of one year from the date the Company received stockholder approval and the date of the Company’s next annual meeting of stockholders is held to effect a reverse stock split of the issued shares of the Company’s common stock, at a ratio within the Reverse Stock Split Range, as determined by the Company’s board of directors (the “Reverse Split Amendment Authorization”). While the Company’s board of directors has not determined to effect a reverse stock split, it may determine that effecting a reverse stock split is necessary in connection with the Company’s ability to satisfy the initial listing requirements to support its plan to be listed on NASDAQ or the NYSE MKT.
	2014 Private Placement
	In four closings in April and May 2014, CPHI completed the 2014 Private Placement and sold an aggregate of 10,260,000 shares of common stock and warrants to purchase an aggregate of 10,260,000 shares of CPHI common stock with an exercise price of $1.00 per share and a five year term. The aggregate gross proceeds of $10,260,000 were allocated between the common stock and the warrants based on their relative fair values which amounted to $5,349,000 for the common stock and $4,911,000 for the warrants.
	Net proceeds after deducting offering expenses were $8,402,000. Aegis Capital Corp acted as the exclusive placement agent for the 2014 Private Placement (the “Placement Agent”). The Placement Agent received a cash fee of $1,023,000 and a non-accountable expense allowance of $308,000. In addition, the Placement Agent received warrants to purchase 2,047,000 shares of common stock with an exercise price of $1.00 per share and a five year term. These warrants contain a cashless exercise feature and the fair value of the warrants was recorded as a stock issuance cost and was netted against the gross proceeds received. Certain members of the management of Aegis Capital Corp. are also shareholders of CPHI.
	In connection with the 2014 Private Placement, CPHI entered into a registration rights agreement with the private placement investors, the Placement Agent and holders of its outstanding warrants. CPHI was required to file a registration statement with the Securities and Exchange Commission (“SEC”) no later than July 29, 2014, covering the resale of the shares of common stock and the shares of common stock underlying the warrants issued in the 2014 Private Placement, as well as the existing warrants. The Company filed a confidential registration statement on Form S-1 on July 2, 2014 and the S-1 was declared effective by the SEC on October 3, 2014. The Company is required to keep the registration statement effective for a period of one year, or until Rule 144 of the Securities Act is available to investors, whichever is earlier.

Stock_Options

Stock Options	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options	10	STOCK OPTIONS
	In 2014, the Company adopted the Corbus 2014 Equity Incentive Plan (the “2014 Plan”). Pursuant to the 2014 Plan, the Company’s Board of Directors may grant incentive and nonqualified stock options and restricted stock to employees, officers, directors, consultants and advisors. At December 31, 2014, there were options to purchase an aggregate of 3,556,691 shares of common stock outstanding under the 2014 Plan and 3,205,952 shares are available for future grants. Options issued under the 2014 Plan are exercisable for up to 10 years from the date of issuance.
	Share-based Compensation
	For stock options issued and outstanding for the years ended December 31, 2014 and 2013, the Company recorded non-cash, stock-based compensation expense of $193,120 and $6,141 respectively, net of estimated forfeitures.
	The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model that uses the assumptions noted in the following table. Due to its limited operating history and limited number of sales of its common stock, the Company estimated its volatility in consideration of a number of factors, including the volatility of comparable public companies. The Company uses historical data, as well as subsequent events occurring prior to the issuance of the financial statements, to estimate option exercises and employee terminations within the valuation model. The expected term of options granted under the 2014 Plan, all of which qualify as “plain vanilla per SEC Staff Accounting Bulletin 107,” is based on the average of the 6.25 years. For non-employee options, the expected term is the contractual term. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option.
	The assumptions used principally in determining the fair value of options granted were as follows:
			2014			2013
	Risk free interest rate			1.88	%		1.19	%
	Expected dividend yield			0	%		0	%
	Expected term in years			6.2			6.25
	Expected volatility			89.75	%		91.95	%
	Estimated forfeiture rate			19.2	%		20	%
	A summary of option activity for years ended December 31, 2014 and 2013 is presented below:
	Options		Shares			Weighted			Weighted		Average
						Average			Average		Intrinsic
						Exercise			Remaining		Value
						Price			Contractual
									Term in
									Years
	Outstanding at December 31, 2012			495,016		$	0.12
	Granted			105,622		$	0.17
	Forfeited			(3,395	)	$	0.17
	Outstanding at December 31, 2013			597,243		$	0.13
	Granted			3,047,139		$	0.95
	Exercised			(87,691	)	$	0.11
	Outstanding at December 31, 2014			3,556,691		$	0.83			8.95		7,689,394
	Vested at December 31, 2014			632,999		$	0.25			6.87		1,732,071
	The weighted average grant-date fair value of options granted during the year ended December 31, 2014 was $0.95 per share. The total fair value of options that were vested as December 31, 2014 was $1,732,071. As of December 31, 2014 there was approximately $864,280 of total unrecognized compensation expense, related to non-vested share-based option compensation arrangements. The unrecognized compensation expense is estimated to be recognized over a period of 3.51 years at December 31, 2014.

Derivative_Instruments

Derivative Instruments	12 Months Ended
	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	11	DERIVATIVE INSTRUMENTS
	The Company issued warrants in 2013 for the purchase of 301,778 shares of common stock, which had provisions that included anti-dilution protection, cashless exercise provisions and, under certain conditions, granted holders the right to request the Company repurchase the warrant. Accordingly, these warrants were considered derivative instruments and as of December 31, 2013, the fair values of $19,932 were recorded respectively as a derivative warrant liability. On June 30, 2014, these warrant agreements were modified to eliminate the anti-dilution protection and accordingly these warrants were no longer considered a derivative liability and the fair value of $48,380 shares was reclassified and charged as an addition to Additional-Paid in Capital.
	To value the derivative warrant liability, the Company used the Black-Scholes option pricing model and assumptions that considered, among other factors, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. The increase in the fair value of the derivative warrant liability at June 30, 2014 from December 31, 2013 was $28,448 and was recognized in the Consolidated Statement of Operations as a change in the fair value of a warrant liability.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
Warrants	12	WARRANTS
	In October 2009, the Company issued warrant agreements with a five year term to holders of convertible bridge notes. Under the terms of each warrant agreement, the exercise price and number of shares were determined upon the completion on a qualified financing, which occurred when the Series A convertible preferred stock financing closed in 2013 at which time the warrants could be exercised to purchase 27,839 shares of common stock at an exercise price of $0.60 per share. The Company valued these warrants at $1,005 and charged the cost to interest expense with an offset to additional paid-in capital.
	In June 2013, the Company issued warrants to purchase 301,778 shares of common stock at an exercise price of $0.66 per share in exchange for services provided. These warrants were valued at $21,910 in June 2013 and expensed to general and administrative expenses with an offset to derivative liability. On June 30, 2014, the Company issued an additional 48,222 warrants to the warrant holder in exchange for a settlement of a claim and modification of the warrant terms and to eliminate the anti-dilution protection (See Note 11).
	In connection with the 2014 Private Placement (See Note 9) the Company issued warrants to investors and former holders of Series A Convertible Preferred Stock to purchase an aggregate of 11,177,612 shares of common stock with an exercise price of $1.00 per share and a five year term. These warrants have a provision that permits the Company to call and redeem the warrants after a thirty day notice period if the stock trades at $2.50 or greater on a volume weighted average basis for at least twenty consecutive trading days. In addition, the Company issued warrants to the Placement Agent to purchase 2,047,000 shares of common stock with an exercise price of $1.00 per share and a five year term. These warrants contain a cashless exercise feature and the fair value of the warrants was recorded as a stock issuance cost and net against the gross proceeds received.
	In August 2014, the Company issued a warrant to a vendor in connection with a debt settlement (See Note 6) for the purchase of 162,539 shares of common stock exercisable at $1.00 per share with a five year term. The Company estimated the fair value of the warrant to be $55,000 based on a Black-Sholes valuation and charged Additional-Paid in Capital.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	13	RELATED PARTY TRANSACTIONS
	In connection with the formation of Corbus Pharmaceutical Holdings, Inc. in December 2013, certain affiliates of Aegis Capital Corp. (the “Placement Agent”) and certain other parties not affiliated with us or the Placement Agent subscribed for an aggregate of 6,000,000 shares of common stock for which they paid an aggregate of $120,000 ($0.02 per share), including David Hochman, one of our directors who purchased 450,000 shares and whose family trust purchased 90,000 shares.
	Following the Initial Closing of the 2014 Private Placement, the Placement Agent has a right to appoint one member of our board of directors for a two-year term (the “Aegis Nominee”). Upon the Initial Closing on April 11, 2014, David Hochman was appointed as the Aegis Nominee.
	On March 21, 2014, we entered into a consulting agreement with Orchestra Medical Ventures, LLC (“Orchestra”), of which David Hochman is Managing Partner. The agreement became effective upon closing of the Merger and provides that Orchestra will render a variety of consulting and advisory services relating principally to identifying and evaluating strategic relationships, licensing opportunities, and business strategies. Orchestra is compensated at the rate of $5,000 per month for twelve months, payable quarterly in advance. For the years ended December 31, 2014 and 2013, the Company paid Orchestra $45,000 and $0, respectively. As of December 31, 2014, $15,000 was payable to Orchestra.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	14	SUBSEQUENT EVENTS
	On January 1, 2015, pursuant to an annual evergreen provision contained in the 2014 Plan, the number of shares reserved for future grants was increased by 1,815,683 shares. As of January 1, 2015, the 2014 Plan had a total reserve of 8,666,017 shares and there were 5,109,326 shares available for future grants.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates
	The process of preparing financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and changes in estimates may occur. The most significant estimates are related to stock based compensation, the value of derivative instruments and the accrual of research and clinical obligations.
	The Company has granted stock options at exercise prices not less than the fair value of its common stock as determined by the board of directors, with input from management. The Company’s board of directors determined the estimated fair value of the common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the historic prices at which the Company sold shares of preferred stock.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within three months from date of purchase to be cash equivalents. Marketable investments are those with original maturities in excess of three months. At December 31, 2014 and 2013, cash equivalents were comprised of money market funds. The Company had no marketable investments at December 31, 2014 and 2013. Cash and cash equivalents consist of the following:
		December 31,
		2014			2013
	Cash	$	10,974		$	100,761
	Money market fund		6,251,471			202,259
		$	6,262,445		$	303,020
Restricted Cash	Restricted Cash
	Restricted cash as of December 31, 2014 was $13,728 and represented a stand-by letter of credit in favor of a landlord (See Note 5).
Financial Instruments	Financial Instruments
	The carrying amounts reported in the consolidated balance sheet for cash and cash equivalents and accounts payable approximate fair value based on the short-term nature of these instruments. The carrying value of loans payable approximate their fair value due to the market terms.
Property and Equipment	Property and Equipment
	Property and Equipment consists of the following:
		December 31,
		2014			2013
	Computer hardware and software	$	17,179		$	—
	Office furniture and equipment		27,960			—
	Leasehold improvements		19,310			—
	Less: accumulated depreciation		(10,405	)		—
	Property and equipment, net	$	54,044		$	—
	The estimated life for all Property and Equipment is 3 years.
Research and Development Expenses	Research and Development Expenses
	Costs incurred for research and development are expensed as incurred. The Company records payments received from research grants as a reduction in Research and Development on the Statement of Operations. For the years ended December 31, 2014 and 2013, the Company reduced Research and Development expense by $49,000 and $205,000, respectively, for research grants.
Accruals for Research and Development Expenses and Clinical Trials	Accruals for Research and Development Expenses and Clinical Trials
	As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate trial expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account discussion with applicable personnel and outside service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the years ended December 31, 2014 and 2013, there were no material adjustments to the Company’s prior period estimates of accrued expenses for clinical trials.
Concentrations of Credit Risk	Concentrations of Credit Risk
	The Company has no significant off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company may from time to time have cash in banks in excess of Federal Deposit Insurance Corporation insurance limits.
Segment Information	Segment Information
	Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as principally one operating segment, which is developing and commercializing therapeutics to treat rare life-threating, rare inflammatory fibrotic diseases. As of December 31, 2014 and 2013, all of the Company’s assets were located in the United States.
Income Taxes	Income Taxes
	For federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in which differences are expected to reverse. A valuation allowance is recorded to reduce a net deferred tax benefit when it is more likely than not that the tax benefit from the deferred tax assets will not be realized. Accordingly, the Company has provided a valuation allowance equal to 100% of the tax benefit in order to eliminate the deferred tax assets amounts. Tax positions taken or expected to be taken in the course of preparing the Company’s tax returns are required to be evaluated to determine whether the tax positions are “more-likely-than-not” of being sustained by the applicable tax authority.
	Tax positions not deemed to meet a more-likely-than-not threshold would be recorded as a tax expense in the current year. There were no uncertain tax positions that require accrual or disclosure to the financial statements as of December 31, 2014 or 2013.
Impairment of Long-lived Assets	Impairment of Long-lived Assets
	The Company continually monitors events and changes in circumstances that could indicate that carrying amounts of long-lived assets may not be recoverable. An impairment loss is recognized when expected cash flows are less than an asset’s carrying value. Accordingly, when indicators of impairment are present, the Company evaluates the carrying value of such assets in relation to the operating performance and future undiscounted cash flows of the underlying assets. The Company’s policy is to record an impairment loss when it is determined that the carrying value of the asset may not be recoverable. No impairment charges were recorded for the years ended December 31, 2014 and 2013.
Share-based Payments	Share-based Payments
	The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement of operations over the service period based on a measurement of fair value for each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. Due to its limited operating history, limited number of sales of its common stock and limited history of its shares being publicly traded, the Company estimates its volatility in consideration of a number of factors including the volatility of comparable public companies.
Derivative Instruments	Derivative Instruments
	The Company generally does not use derivative instruments to hedge exposures to cash-flow or market risks; however, certain warrants to purchase common stock that do not meet the requirements for classification as equity are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. Such financial instruments are initially recorded at fair value with subsequent changes in fair value charged (credited) to operations in each reporting period. If these instruments subsequently meet the requirements for classification as equity, the Company reclassifies the fair value to equity.
Net Loss Per Common Share	Net Loss Per Common Share
	Basic net loss per share of the Company’s common stock has been computed by dividing net loss by the weighted average number of shares outstanding during the period. Diluted net income per share of the Company’s common stock has been computed by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding stock options, warrants and convertible securities. Diluted net loss per share of the Company’s common stock has been computed by dividing the net loss for the period by the weighted average number of shares of the Company’s common stock outstanding during such period. In a net loss period, options, warrants and convertible securities are anti-dilutive and therefore excluded from diluted loss per share calculations. The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2014 and 2013:
		Years Ended December 31,
		2014			2013
	Basic and diluted net loss per share of common stock:
	Net loss	$	(2,540,485	)	$	(602,350	)
	Net loss applicable to common stockholders		(2,540,485	)		(602,350	)
	Weighted average shares of common stock outstanding		20,159,861			6,964,788
	Net loss per share of common stock-basic and diluted	$	(0.13	)	$	(0.09	)
	The following potentially dilutive securities outstanding at December 31, 2014 and 2013 have been excluded from the computation of dilutive weighted average shares outstanding as the inclusion would be antidilutive.
		December 31,
		2014			2013
	Preferred stock		—			1,646,157
	Warrants		13,709,977			329,617
	Stock options		3,556,691			528,154
			17,266,668			2,503,928
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern, which states management should evaluate whether there are conditions or events, considered in the aggregate, that raise a substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Management’s evaluation should be based on
	relevant conditions and events that are known and likely to occur at the date that the financial statements are issued. The standard update will be effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter, however, early application is permitted. Management does not expect the adoption of ASU 2014-15 to have material impact on the Company’s consolidated financial statements, although there may be additional disclosures upon adoption.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Cash and Cash Equivalents	Cash and cash equivalents consist of the following:
		December 31,
		2014			2013
	Cash	$	10,974		$	100,761
	Money market fund		6,251,471			202,259
		$	6,262,445		$	303,020
Summary of Property and Equipment	Property and Equipment consists of the following:
		December 31,
		2014			2013
	Computer hardware and software	$	17,179		$	—
	Office furniture and equipment		27,960			—
	Leasehold improvements		19,310			—
	Less: accumulated depreciation		(10,405	)		—
	Property and equipment, net	$	54,044		$	—
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2014 and 2013:
		Years Ended December 31,
		2014			2013
	Basic and diluted net loss per share of common stock:
	Net loss	$	(2,540,485	)	$	(602,350	)
	Net loss applicable to common stockholders		(2,540,485	)		(602,350	)
	Weighted average shares of common stock outstanding		20,159,861			6,964,788
	Net loss per share of common stock-basic and diluted	$	(0.13	)	$	(0.09	)
Potentially Dilutive Securities Excluded from the Computation of Dilutive Weighted Average Shares Outstanding	The following potentially dilutive securities outstanding at December 31, 2014 and 2013 have been excluded from the computation of dilutive weighted average shares outstanding as the inclusion would be antidilutive.
		December 31,
		2014			2013
	Preferred stock		—			1,646,157
	Warrants		13,709,977			329,617
	Stock options		3,556,691			528,154
			17,266,668			2,503,928

Fair_Value_of_Assets_and_Liabi1

Fair Value of Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Schedule of Fair Value Assumptions	The warrant derivative liability was re-measured at June 30, 2014 prior to reclassification using the Black-Scholes option pricing model based on the following assumptions:
		As of June 30,
		2014
	Risk free interest rate		1.25	%
	Expected dividend yield		0	%
	Contractual term		3.97
	Expected volatility		66	%
Assets and Liabilities Measured at Fair Value on Recurring Basis	Assets and liabilities measured at fair value on a recurring basis are summarized below:
		December 31, 2014
		Level 1			Level 2		Level 3			Total
	Liabilities:
	Derivative warrant liability at December 31, 2013	$	—		$	—	$	19,932		$	19,932
	Change in fair value of the derivative warrant liability		—			—		28,448			28,448
	Reclassification of derivative warrant liability		—			—		(48,380	)		(48,380	)
	Derivative warrant liability at December 31, 2014	$	—		$	—	$	—		$	—
		31-Dec-13
		Level 1			Level 2		Level 3			Total
	Liabilities:
	Derivative warrant liability at December 31, 2012	$	—		$	—	$	—		$	—
	Derivative warrant liability recored for warrants issued		—			—		21,910			21,910
	Change in fair value of the derivative warrant liability		—			—		(1,978	)		(1,978	)
	Derivative warrant liability at December 31, 2013	$	—		$	—	$	19,932		$	19,932

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rent Commitments
	Pursuant to the terms of the Company’s non-cancelable lease agreements in effect at December 31, 2014, the future minimum rent commitments are as follows:
	2015	$	55,498
	2016		56,511
	2017		28,464
	Total	$	140,473

Notes_Payable_Tables

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consisted of the following:
		December 31,
		2014			2013
	Notes payable	$	144,389		$	638,078
	Less: current portion		(144,389	)		(306,835	)
		$	—		$	331,243

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Components of Net Deferred Tax Asset	Significant components of the Company’s net deferred tax asset are as follows:
		December 31,
		2014			2013
	NOL Carryforward	$	1,408,745		$	511,595
	Tax credits		167,127			73,206
	Stock Based Compensation		60,373			2,412
	Other temporary differences		128,093			122,573
	Subtotal		1,764,338			709,786
	Valuation Allowance		(1,764,338	)		(709,786	)
	Net Deferred Tax asset	$	—		$	—
Schedule of Effective Income Tax Rate Reconciliation	Income tax benefits computed using the federal statutory income tax rate differs from the Company’s effective tax rate primarily due to the following:
		December 31,
		2014			2013
	Tax provision at statutory rate		34	%		34	%
	State taxes, net of federal benefit		5.03	%		5.09	%
	Permanent differences		-0.47	%		-1.19	%
	Tax Credits		3.37	%		4.2	%
	Other		0.21	%		7.47	%
	Decrease in valuation reserve		-42.14	%		-49.57	%
	Total		0	%		0	%

Stock_Options_Tables

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Assumptions Used Principally in Determining Fair Value of Options Granted	The assumptions used principally in determining the fair value of options granted were as follows:
		2014			2013
	Risk free interest rate		1.88	%		1.19	%
	Expected dividend yield		0	%		0	%
	Expected term in years		6.2			6.25
	Expected volatility		89.75	%		91.95	%
	Estimated forfeiture rate		19.2	%		20	%
Summary of Option Activity	A summary of option activity for years ended December 31, 2014 and 2013 is presented below:
	Options	Shares			Weighted			Weighted		Average
					Average			Average		Intrinsic
					Exercise			Remaining		Value
					Price			Contractual
								Term in
								Years
	Outstanding at December 31, 2012		495,016		$	0.12
	Granted		105,622		$	0.17
	Forfeited		(3,395	)	$	0.17
	Outstanding at December 31, 2013		597,243		$	0.13
	Granted		3,047,139		$	0.95
	Exercised		(87,691	)	$	0.11
	Outstanding at December 31, 2014		3,556,691		$	0.83			8.95		7,689,394
	Vested at December 31, 2014		632,999		$	0.25			6.87		1,732,071

Nature_of_Operations_Additiona

Nature of Operations - Additional Information (Detail) (USD $)	12 Months Ended	0 Months Ended
	Dec. 31, 2014	Apr. 11, 2014	Aug. 31, 2014	Dec. 31, 2013	Jun. 30, 2013	Oct. 31, 2009
Nature of Operations [Line Items]
Number of common shares called by warrants	33,333		162,539	301,778	301,778	27,839
Common stock, shares outstanding	25,938,332			6,964,788
Private placement of equity, net proceeds	$8,402,000
JB Therapeutics Inc. [Member]
Nature of Operations [Line Items]
Conversion of stock, shares issued		9,000,000
Number of shares converted to common stock		5,964,649
Number of common shares called by warrants		377,839
Number of options to purchase shares of common stock		905,334
Exchange ratio of shares	1.5089			1.5089
Common stock, shares outstanding		6,000,000
Series A Preferred Stock [Member] | JB Therapeutics Inc. [Member]
Nature of Operations [Line Items]
Number of common shares called by warrants		917,612
Minimum [Member] | JB Therapeutics Inc. [Member]
Nature of Operations [Line Items]
Common stock warrants, exercise price		0.6
Options exercise price		0.11
Maximum [Member] | JB Therapeutics Inc. [Member]
Nature of Operations [Line Items]
Common stock warrants, exercise price		0.66
Options exercise price		0.17

Liquidity_Additional_Informati

Liquidity - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Accumulated deficit	($4,427,075)	($1,886,590)

Significant_Accounting_Policie3

Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
	Segment
Significant Accounting Policies [Line Items]
Marketable investments	$0	$0
Restricted cash	13,728
Estimated useful life of all property and equipment	3 years
Reduction in research and development expense	49,000	205,000
Operating segments	1
Valuation allowance	100.00%
Uncertain tax position	0	0
Impairment charges	$0	$0
Maximum [Member]
Significant Accounting Policies [Line Items]
Cash and cash equivalents maturity period	3 months
Minimum [Member]
Significant Accounting Policies [Line Items]
Marketable investments maturity period	3 months

Significant_Accounting_Policie4

Significant Accounting Policies - Schedule of Cash and Cash Equivalents (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash and Cash Equivalents [Abstract]
Cash	$10,974	$100,761
Money market fund	6,251,471	202,259
Cash and cash equivalents	$6,262,445	$303,020	$542,483

Significant_Accounting_Policie5

Significant Accounting Policies - Summary of Property and Equipment (Detail) (USD $)	Dec. 31, 2014
Property Plant And Equipment Capitalized Interest Costs [Abstract]
Computer hardware and software	$17,179
Office furniture and equipment	27,960
Leasehold improvements	19,310
Less: accumulated depreciation	-10,405
Property and equipment, net	$54,044

Significant_Accounting_Policie6

Significant Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Basic and diluted net loss per share of common stock:
Net loss	($2,540,485)	($602,350)
Net loss applicable to common stockholders	($2,540,485)	($602,350)
Weighted average shares of common stock outstanding	20,159,861	6,964,788
Net loss per share of common stock-basic and diluted	($0.13)	($0.09)

Significant_Accounting_Policie7

Significant Accounting Policies - Potential Dilutive Securities Excluded from the Computation of Dilutive Weighted Average Shares Outstanding (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred stock	17,266,668	2,503,928
Warrant [Member]
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred stock	13,709,977	329,617
Stock Options [Member]
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred stock	3,556,691	528,154
Preferred Stock [Member]
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred stock		1,646,157

Fair_Value_of_Assets_and_Liabi2

Fair Value of Assets and Liabilities - Schedule of Fair Value Assumptions (Detail)	0 Months Ended
	Jun. 30, 2014
Debt Instrument Fair Value Carrying Value [Abstract]
Risk free interest rate	1.25%
Expected dividend yield	0.00%
Contractual term	3 years 11 months 19 days
Expected volatility	66.00%

Fair_Value_of_Assets_and_Liabi3

Fair Value of Assets and Liabilities - Additional Information (Detail) (USD $)	Dec. 31, 2014
Debt Instrument Fair Value Carrying Value [Abstract]
Derivative warrant liability	$0

Fair_Value_of_Assets_and_Liabi4

Fair Value of Assets and Liabilities - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative warrant liability recorded for warrants issued			$19,932
Change in fair value of the derivative warrant liability	28,448	28,448	-1,978
Derivative warrant liability, Ending balance		0
Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative warrant liability, Beginning balance	19,932	19,932
Change in fair value of the derivative warrant liability		28,448	-1,978
Reclassification of derivative warrant liability		-48,380
Derivative warrant liability, Ending balance			19,932
Fair Value, Measurements, Recurring [Member] | Warrant [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative warrant liability recorded for warrants issued			21,910
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative warrant liability, Beginning balance	19,932	19,932
Change in fair value of the derivative warrant liability		28,448	-1,978
Reclassification of derivative warrant liability		-48,380
Derivative warrant liability, Ending balance			19,932
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative warrant liability recorded for warrants issued			$21,910

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Commitment And Contingencies [Line Items]
Terms of lease	3 years
Standby letters of credit	$13,728
Rent expense	$35,550	$0
Norwood, Ma [Member]
Commitment And Contingencies [Line Items]
Area of office space	2,387

Commitments_and_Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Rent Commitments (Detail) (USD $)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
2015	$55,498
2016	56,511
2017	28,464
Total	$140,473

Notes_Payable_Additional_Infor

Notes Payable - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended		1 Months Ended
	Oct. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2014	Jun. 30, 2013	Oct. 31, 2009	Apr. 11, 2014
Debt Instrument [Line Items]
Annual interest rate	3.25%
Notes payable		$144,389	$638,078
Common stock, shares issued		25,938,332	6,964,788
Number of common stock called by warrants		33,333	301,778	162,539	301,778	27,839
Common stock, term		5 years
Common stock, issued value		2,594	696
Estimated fair value of warrants				55,000
Gain on the settlement of debt		145,006
Interest expense		24,021	45,114
Proceeds from issuance of notes payable	192,000	192,000	7,252
Principal and interest payable	24,293
Warrant [Member]
Debt Instrument [Line Items]
Common stock, shares issued		33,333
2014 Private Placement [Member]
Debt Instrument [Line Items]
Common stock, shares issued							6,000,000
Number of common stock called by warrants		10,260,000
Common stock, cost exercisable per share		$1
2014 Private Placement [Member] | Common Stock And Warrants [Member]
Debt Instrument [Line Items]
Sale price for one share of common stock and one warrant		$1
Vendor One [Member]
Debt Instrument [Line Items]
Annual interest rate		7.00%
Settlement agreement, repayment		90,000		631,000
Notes payable				531,000
Accrued interest				93,000
Accounts payable				7,000
Common stock, shares issued		541,948
Number of common stock called by warrants		162,539
Common stock, cost exercisable per share		$1
Vendor Two [Member]
Debt Instrument [Line Items]
Notes payable		75,244
Number of periodic payments		Four equal monthly principal installments
Principal installment		25,081
Estimate of Fair Value Measurement [Member] | 2014 Private Placement [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Estimated fair value per share		$0.63
Estimate of Fair Value Measurement [Member] | 2014 Private Placement [Member] | Warrant [Member]
Debt Instrument [Line Items]
Estimated fair value per share		$0.37
Black Scholes [Member]
Debt Instrument [Line Items]
Common stock, issued value		341,000
Estimated fair value of warrants		$55,000
Minimum [Member]
Debt Instrument [Line Items]
Common stock, term	8 months

Notes_Payable_Schedule_of_Note

Notes Payable - Schedule of Notes Payable (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Equity Method Investments And Cost Method Investments [Abstract]
Notes payable	$144,389	$638,078
Less: current portion	-144,389	-306,835
Total		$331,243

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Provision (Benefit) for federal and state income tax	$0
Net operating loss carryforwards	1,408,745	511,595
Tax credit carryforwards	167,127	73,206
Uncertain tax position	$0	$0
Federal [Member]
Income Taxes [Line Items]
Operating loss carryforwards expiration year	2029
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Operating loss carryforwards expiration year	2014

Income_Taxes_Components_of_Net

Income Taxes - Components of Net Deferred Tax Asset (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
NOL Carryforward	$1,408,745	$511,595
Tax credits	167,127	73,206
Stock Based Compensation	60,373	2,412
Other temporary differences	128,093	122,573
Subtotal	1,764,338	709,786
Valuation Allowance	-1,764,338	-709,786
Net Deferred Tax asset	$0	$0

Income_Taxes_Schedule_of_Effec

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Tax provision at statutory rate	34.00%	34.00%
State taxes, net of federal benefit	5.03%	5.09%
Permanent differences	-0.47%	-1.19%
Tax Credits	3.37%	4.20%
Other	0.21%	7.47%
Decrease in valuation reserve	-42.14%	-49.57%
Total	0.00%	0.00%

Series_A_Preferred_Stock_Addit

Series A Preferred Stock - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Apr. 11, 2014	Dec. 31, 2013	Dec. 31, 2014
Class of Stock [Line Items]
Convertible preferred stock, shares issued			0
Common Stock [Member]
Class of Stock [Line Items]
Conversion of stock, shares issued	2,035,212
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock converted, shares	1,835,212
Convertible preferred stock, shares issued		198,808
Convertible preferred stock, proceeds raised		$120,000
Series A Non-Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock converted, shares	200,000

Common_Stock_Additional_Inform

Common Stock - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended		12 Months Ended	0 Months Ended
	Oct. 08, 2014	Aug. 31, 2014	Oct. 31, 2009	Dec. 31, 2014	Apr. 11, 2014	Dec. 31, 2013	Jun. 30, 2013
Common Stock [Line Items]
Common stock, shares authorized				150,000,000		150,000,000
Common stock, par value				$0.00		$0.00
Common stock, shares issued				25,938,332		6,964,788
Common stock, shares outstanding				25,938,332		6,964,788
Net Proceeds from common stock				$10,305,161
Options to purchase shares of common stock				87,691
Number of common stock called by warrants		162,539	27,839	33,333		301,778	301,778
Common stock exercised under cashless exercise provision				21,500
Reverse stock split	Reverse stock split within a range of 1:1.25 to 1:5
Warrant exercisable term		5 years	5 years
Net proceeds after deducting offering expense				8,402,000
Settlement Agreement [Member]
Common Stock [Line Items]
Common stock, shares issued		541,948
Series A Convertible Preferred Stock [Member]
Common Stock [Line Items]
Preferred stock, shares converted					1,835,212
Series A Non-Convertible Preferred Stock [Member]
Common Stock [Line Items]
Preferred stock, shares converted					200,000
Stock Options [Member]
Common Stock [Line Items]
Common stock, shares issued				87,691
Net Proceeds from common stock				4,450
Minimum [Member]
Common Stock [Line Items]
Reverse Stock Split Range	0.2
Maximum [Member]
Common Stock [Line Items]
Reverse Stock Split Range	0.8
Common Stock [Member]
Common Stock [Line Items]
Conversion of stock, shares issued					2,035,212
Options to purchase shares of common stock				87,691
Aggregate common stock sold, shares				6,000,000
Fair value of stock and warrants				600
Warrant [Member]
Common Stock [Line Items]
Common stock, shares issued				33,333
Net Proceeds from common stock				33,333
Shares issued under cashless exercise of options				15,360
2014 Private Placement [Member]
Common Stock [Line Items]
Common stock, shares issued					6,000,000
Number of common stock called by warrants				10,260,000
Common stock warrants, exercise price				$1
Warrant exercisable term				5 years
Fair value of stock and warrants				10,260,000
2014 Private Placement [Member] | Placement Agent Member
Common Stock [Line Items]
Number of common stock called by warrants				2,047,000
Warrant exercisable term				5 years
Placement agent, cash fee				1,023,000
Placement agent, non-accountable expense				308,000
2014 Private Placement [Member] | Common Stock [Member]
Common Stock [Line Items]
Aggregate common stock sold, shares				10,260,000
Fair value of stock and warrants				5,349,000
2014 Private Placement [Member] | Warrant [Member]
Common Stock [Line Items]
Fair value of stock and warrants				$4,911,000

Stock_Options_Additional_Infor

Stock Options - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$193,120	$6,141
Weighted average grant-date fair value, Options granted	$0.95
Total fair value of options, Vested	1,732,071
Share based compensation expense	864,280
Share based compensation expense, not yet recognized period of recognition	3 years 6 months 4 days
Two Thousand Fourteen Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate Common stock available for stock options granted, shares	3,556,691
Shares available for grant	3,205,952
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$193,120	$6,141
Expected term in years	6 years 2 months 12 days	6 years 3 months
Stock Options [Member] | Two Thousand Fourteen Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, Expiration period	10 years

Stock_Options_Summary_of_Assum

Stock Options - Summary of Assumptions Used Principally in Determining Fair Value of Options Granted (Detail) (Stock Options [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.88%	1.19%
Expected dividend yield	0.00%	0.00%
Expected term in years	6 years 2 months 12 days	6 years 3 months
Expected volatility	89.75%	91.95%
Estimated forfeiture rate	19.20%	20.00%

Stock_Options_Summary_of_Optio

Stock Options - Summary of Option Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shares Outstanding, Beginning balance	597,243	495,016
Shares, Granted	3,047,139	105,622
Shares, Forfeited		-3,395
Shares, Exercised	-87,691
Shares Outstanding, Ending balance	3,556,691	597,243
Weighted Average Exercise Price Outstanding, Beginning balance	$0.13	$0.12
Shares, Vested	632,999
Weighted Average Exercise Price, Granted	$0.95	$0.17
Weighted Average Exercise Price, Forfeited		$0.17
Weighted Average Exercise Price,Exercised	$0.11
Weighted Average Exercise Price Outstanding, Ending balance	$0.83	$0.13
Weighted Average Remaining Contractual Term Outstanding in Years, Ending balance	8 years 11 months 12 days
Weighted Average Exercise Price, Vested	$0.25
Weighted Average Remaining Contractual Term in Years, Vested	6 years 10 months 13 days
Average Intrinsic Value, Ending Balance	$7,689,394
Average Intrinsic Value, Vested	$1,732,071

Derivative_Instruments_Additio

Derivative Instruments - Additional Information (Detail) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2014	Jun. 30, 2013	Oct. 31, 2009
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Number of shares of common stock called by warrants		33,333	301,778	162,539	301,778	27,839
Derivative warrant liability			$19,932
Addition to Additional-Paid in Capital	48,380
Changes in fair value of derivative warrant liability	$28,448	$28,448	($1,978)

Warrants_Additional_Informatio

Warrants - Additional Information (Detail) (USD $)	1 Months Ended			6 Months Ended	12 Months Ended
	Aug. 31, 2014	Jun. 30, 2013	Oct. 31, 2009	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Warrant exercisable term	5 years		5 years
Number of shares of common stock called by warrants	162,539	301,778	27,839		33,333	301,778
Warrants, exercise price per share	$1	$0.66	$0.60
Changes in fair value of derivative warrant liability				$28,448	$28,448	($1,978)
Estimated fair value of warrants	55,000
Additional warrants issued		48,222
2014 Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrant exercisable term					5 years
Number of shares of common stock called by warrants					10,260,000
Placement Agent Member | 2014 Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrant exercisable term					5 years
Number of shares of common stock called by warrants					2,047,000
Warrants, exercise price per share					$1
Debt instrument redemption description					These warrants have a provision that permits the Company to call and redeem the warrants after a thirty day notice period if the stock trades at $2.50 or greater on a volume weighted average basis for at least twenty consecutive trading days
Series A Convertible Preferred Stock [Member] | Investors And Former Holders Of Series A Convertible Preferred Stock [Member] | 2014 Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrant exercisable term					5 years
Number of shares of common stock called by warrants					11,177,612
Warrants, exercise price per share					$1
Interest Expense [Member]
Class of Warrant or Right [Line Items]
Changes in fair value of derivative warrant liability			1,005
General and Administrative Expense [Member]
Class of Warrant or Right [Line Items]
Estimated fair value of warrants		$21,910

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Mar. 24, 2014	Dec. 31, 2014	Dec. 31, 2013
Schedule of Other Related Party Transactions [Line Items]
Common stock share issued		25,938,332	6,964,788
Common stock, issued value		$2,594	$696
Common stock value per share		$0.00	$0.00
Aegis Capital Corp and Other Affiliates [Member]
Schedule of Other Related Party Transactions [Line Items]
Common stock share issued			6,000,000
Common stock, issued value			120,000
Common stock value per share			$0.02
Director [Member]
Schedule of Other Related Party Transactions [Line Items]
Common stock share issued			450,000
Trust [Member]
Schedule of Other Related Party Transactions [Line Items]
Common stock share issued			90,000
Aegis Capital Corp [Member]
Schedule of Other Related Party Transactions [Line Items]
Description of private placement		The Placement Agent has a right to appoint one member of our board of directors for a two-year term (the "Aegis Nominee").
Orchestra Medical Ventures LLC [Member]
Schedule of Other Related Party Transactions [Line Items]
Compensation rate per month	5,000
Amount paid to the service		45,000	0
Amount payable to the service		$15,000

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (Two Thousand Fourteen Equity Incentive Plan [Member])	0 Months Ended
	Jan. 01, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Total shares reserved, stock option plan		3,556,691
Shares available for grant		3,205,952
Stock Options [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Increase in number of shares reserved for future grants	1,815,683
Total shares reserved, stock option plan	8,666,017
Shares available for grant	5,109,326